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Introduction
Behcet’s disease (BD) is a multisystemic inflammatory
disease characterized by oral and genital aphthosis as
well as inflammation of the eye, skin, joints, gastroin-
testinal tract, vasculature, and even the central nervous
system. One of the most common devastating con-
ditions is recurring severe intraocular inflammation
(uveitis) involving any area of the posterior segment.
Uveitis in BD leads to optic nerve and chorioretinal
atrophy and, eventually, blindness.
The geographical distribution of BD, mainly span-
ning countries between the Mediterranean countries
and Japan, led to the synonym of Silk Road disease.1
It is conjectured that Chinese living between the 2
areas are at greater risk. But a detailed search of the
literature via MEDLINE (PubMed) revealed little infor-
mation regarding the disease in Chinese.2–5 A joint
survey of 6 major ophthalmological departments per-
formed in 19906 found the prevalence of BD in Taiwan
to be about 1 per 105, which is much lower than the
prevalence in Silk Road countries.7
Recently, the number of patients with newly devel-
oped BD decreased in Japan,8,9 and the visual progno-
sis for such patients seems to have improved in Japan
and Turkey.9,10 In this study, clinical features, treat-
ment, association of the genetic factor of HLA-B51
antigen, and visual outcome were assessed in all Chinese
patients who were seen consecutively in a uveitis clinic
at a tertiary ophthalmology center in Taiwan during 
a 20-year period. Furthermore, patients who visited
between 1984 and 1993 were compared with patients
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who visited between 1994 and 2003. Our purpose
was to describe and compare the disease presentation
and visual outcome in these affected groups.
Methods
The study was approved by the Institutional Review
Board of Taipei Veterans General Hospital. Diagnosis
of BD was made on the basis of the revised criteria of
the Behcet’s Disease Research Committee of Japan in
2003.11 Recurrent aphthous ulcers of oral mucosa,
skin lesions, ocular inflammation, and genital ulcers
are the main symptoms. Arthritis without deformity
or sclerosis, epididymitis, gastrointestinal lesions, vas-
cular lesions, and central nervous system lesions are
additional symptoms. A diagnosis of BD was made for
those who manifested 3 main symptoms or typical ocu-
lar lesion and another main symptom (1 main symp-
tom was equal to 2 additional symptoms) during the
clinical course.
All the patients included in this study were Chinese,
had BD with ocular involvement, and were seen consec-
utively in the Uveitis Clinic of Taipei Veterans General
Hospital during a 20-year period from January 1984
to December 2003. This Uveitis Clinic was established
in 1984 and was the first one to be in a Chinese area.12
The majority of patients were referred from all over
Taiwan for further diagnosis and management. A rheu-
matologist was consulted upon diagnosis of uveitis with
BD. A complete ocular examination was performed 
at each visit. Patients who visited the clinic between
1984 and 1993 were classified into group A, and
those who visited between 1994 and 2003 into group
B. Ocular manifestations were divided into anterior
uveitis, posterior uveitis, or panuveitis when both were
involved. When the manifestations of the 2 eyes of the
same patient differed, it was defined as asymmetric.
Treatment protocol, which changed during the
study period, was based on the severity of the disease.
If the uveitis episode was limited in the anterior and/
or intermediate segment, then a short course of topi-
cal steroid was given. If the uveitis episode was acute
and involved the posterior segment, presenting with
retinitis with retinal exudates or vasculitis with hem-
orrhage, then systemic corticosteroids with an evaluated
dosage were given. In more severe cases, especially
retinitis involving the macula, high-dose intravenous
steroid therapy was given. On the other hand, accord-
ing to disease activity, management was with observa-
tion only if the uveitis was mild and rarely recurred.
Generally, 1.0–1.5 mg/day colchicine was used as the
first choice for preventing the recurrence of uveitis.
When patients were not responsive to colchicine,
cyclosporin-A and/or immunosuppressive drugs were
used. Cyclosporin A was given in a dosage of 3–5 mg/
kg/day since 1990. Immunosuppressive drugs includ-
ing cyclophosphamide (2.5 mg/kg/day), chlorambucil
(0.1–0.2 mg/kg/day), azathioprine (1–2.5 mg/kg/
day), methotrexate (7.5–20 mg/week), and plaquenil
(200–400 mg/day) were used. Those drugs were used
in combination or alternatively according to the eye
condition and response, and the potential side effects
were closely monitored.
Visual acuities (VAs) of counting fingers, hand
movement, light perception (LP), and no LP were
given values of 6/1,200, 6/12,000, 6/30,000, and
6/60,000, respectively, to facilitate their conversion
into logarithmic values.9 VAs better than 6/60 were
defined as useful vision. Because VAs were usually
severely affected during the inflammatory episodes, we
defined potential VA as the best-corrected VA recorded
at presentation if the eye was not affected or after the
first observed inflammatory episode had resolved and
vision had stabilized. For analyses of visual outcomes,
only those eyes with potential VAs better than 6/60
were included. A simplified method9 was used to deter-
mine the stability of vision of those with potential VAs
better than 6/60. The potential VA (α) was defined
as mentioned above, and the final VA (β) was defined
as the best-corrected VA during the month before the
last visit or at the time when vision loss was irreversible.
The t value is the time interval in months between the
α and β measurements. The γ value was calculated
using the following equation:
γ = (logMARα − logMARβ)/t
Data analyses were performed using SPSS version
13.0 (SPSS Inc., Chicago, IL, USA). The normality
of each variable was examined using the Shapiro-Wilk
test. The Mann-Whitney U test was used to compare
nonparametric continuous variables. Categorical vari-
ables were analyzed using the χ2 test or Fisher’s exact
test. The Kaplan-Meier method was used to estimate
survival curves, and the differences between groups and
genders were evaluated by the log-rank test. The level
of statistical significance was set at less than 0.05.
Results
Demographics
A total of 227 patients were included; their demo-
graphic characteristics are shown in Table 1. The male-
to-female ratio was 1.6. The mean age at the time of
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uveitis onset was 30.8 ± 10.9 years. Although the dif-
ferences between sexes and groups were not signifi-
cant, it was quite remarkable in age distribution by
decades, as shown in Figure 1. Association of HLA-B51
antigen was observed in 51 (35.7%) of 143 assessed
patients, and there was no difference between genders
or groups.
Ocular manifestations
The ocular manifestations are summarized in Table 2.
The most common manifestation was panuveitis.
Binocular involvement occurred in 82.4% of patients.
The percentage of panuveitis, bilateral eye involve-
ment, and symmetric eye presentation was decreased
in group B. There was no difference in type of uveitis
or symmetry of ocular involvement between males
and females.
Extraocular manifestations
The extraocular manifestations are summarized in
Table 3. The most common manifestation was aphthous
ulcer, occurring in 221 (97.4%) patients. The remaining
6 patients manifested skin lesions of erythema nodosum
in addition to ocular symptoms. The frequencies of skin
and gastrointestinal lesions were significantly increased
in males, and those of skin lesions and genital ulcers
were decreased in group B.
Treatment
The treatment is summarized in Table 4. Usage of
colchicine, chlorambucil, and oral corticosteroids was
significantly decreased and usage of cyclosporin, aza-
thioprine, and methotrexate was increased in group B.
Visual outcomes
A total of 414 eyes were included (187 patients with
bilateral involvement, 36 patients with unilateral involve-
ment, and 4 1-eyed patients). Excluding 5 eyes with-
out follow-up, potential VA was determined in 409
eyes. The visual outcomes of those eyes are summa-
rized in Table 5. Females and patients in group B
were more likely to have potential VA better than
Figure 1. Age of uveitis onset by decade between males and
females (p = 0.001).
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Table 1. Patients’ profiles and comparison between groups A and B
Total Group A (1984–1993) Group B (1994–2003) p
No. of patients 227 95 132
Male:female 140:87 64:31 76:56 0.134*
Observation length (mo) 51.6 ± 57.2 83.4 ± 71.2 28.8 ± 27.2 0.000†
(range, 0–227) (range, 0–227) (range, 0–117)
Time between uveitis onset and 26.9 ± 47.3 23.1 ± 28.2 29.7 ± 57.2 0.715†
first visit (mo) (range, 0–492) (range, 0–144) (range, 0–492)
Average age at uveitis onset (yr) 30.8 ± 10.9 31.7 ± 9.2 30.1 ± 12.0 0.286†
(range, 6–62) (range, 12–55) (range, 6–62)
Uniocular:binocular 36:187 10:85 26:102 0.050*
HLA-B51 (positive:negative)‡ 51:92 27:40 24:52 0.277*
*Calculated by χ2 test; †calculated by Mann-Whitney U test; ‡based on available data of 143 patients.
Table 2. Comparisons of ocular manifestations between groups
A and B
Total Group A Group B p
Type of uveitis
Anterior 37 7 30 0.001*
Posterior 90 30 60 0.016*
Panuveitis 287 147 140 0.000*
Ocular involvement
Uniocular vs. 36:187 3:89 33:98 0.000†
binocular
Binocular 187 89 98
Symmetric 167 89 78 0.000†
Asymmetric 20 0 20
Single eye 4 3 1
*Calculated by χ2 test; †calculated by Fisher’s exact test.
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6/60. For eyes with potential VA better than 6/60, a
total of 63 (19.1%) eyes lost useful vision irreversibly
during follow-up, and males and patients in group B
suffered more frequently from permanent VA loss. Both
at the first and last visits for the 329 eyes with poten-
tial VAs better than 0.1, the percentage of eyes with
good VA increased and that with poor VA decreased
in group B and in females (p = 0.000 and p = 0.000,
respectively; Figure 2). The mean time to loss of use-
ful vision was 51.0 ± 40.3 months. There was no sig-
nificant gender or group difference in mean time to
this loss. The average γ value was –0.021 ± 0.096. The
speed of deterioration of VA decreased significantly in
group B and females.
Kaplan-Meier survival analysis estimated the risk
of loss of useful vision to be 22.6% at 5 years, 43.0% 
at 10 years, and 58.5% at 15 years. A significant gen-
der difference was found (Figure 3). The risk of loss
seemed to plateau after around 10 years in females.
When comparing the risk of VA loss between groups,
there was no significant difference for all patients, males
or females.
Discussion
Behcet’s disease was named by the Turkish physician
Huluci Behcet,13 who in 1937 described the classic
trisymptom complex of hypopyon, iritis, and orogeni-
tal aphthosis. The Greek physician Adamantiades had
reported the disease 6 year earlier, accounting for the
alternative eponym Adamantiades-Behcet disease.14
However, the father of medicine, Hippocrates of Kos
(460–377 BC), first described an endemic disease in Asia
Minor characterized by “aphthous ulcerations”, “deflux-
ions about the genital parts… watery ophthalmies of a
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Table 4. Comparisons of numbers of patients receiving or not
receiving agents between groups A and B
Group A Group B
p
(n = 95) (n = 132)
Patients receiving:patients 
not receiving
Colchicine 85:10 84:48 0.000*
Cyclosporine 15:80 55:77 0.000*
Cyclophosphamide 8:87 8:124 0.493*
Chlorambucil 9:86 1:131 0.002†
Azathioprine 2:93 23:109 0.000†
Methotrexate 0:95 11:121 0.002†
Plaquenil 1:94 1:131 0.826†
Oral corticosteroids 67:28 53:79 0.000*
*Calculated by χ2 test; †calculated by Fisher’s exact test.
chronic character… which destroyed the sight of many
persons”.15 A similar description of a disease named
“Hu For” by Dr Chang Chung-Ching (AD 142–220,
East Han Dynasty) was also found in ancient China.
In the Chin Kuei Yao Lueh and Shang-Han Lun, 
Hu For is described as a syndrome comprising several
common elements: Hu indicates the ulcers involving
the genital organs, For indicates ulcers involving the
oropharynx, “the eyes of the patient may be as red as
those of a cushat”, and “if the disease extends with the
route of Ki onto the body surface, skin abscesses with
pustule formation can be observed”.
There are more than 7 diagnostic criteria for BD.7
The International Study Group Criteria for Behcet’s
Disease16 is the most commonly used. But the speci-
ficity of ocular inflammation makes it as important as
2 other main symptoms used for diagnosis in the revised
diagnostic criteria proposed by the Behcet’s Disease
Research Committee of Japan.11 So most studies on BD
with ocular involvement, including this study, have used
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Table 5. Comparisons of visual outcomes between sexes and groups
Total Male Female p Group A Group B p
Total eyes with follow-up 409 251 158 178 231
Potential VA ≤ 6/60 80 62 18 0.000* 59 21 0.000*
Potential VA > 6/60 329
Irreversible vision loss 63 51 12 0.000* 35 28 0.000*
Mean time to vision 51.0 ± 40.3 49.1 ± 40.4 59.3 ± 40.2 0.426† 57.7 ± 44.4 42.7 ± 33.3 0.186†
loss (mo)
γ value −0.021 ± 0.096 −0.032 ± 0.123 −0.007 ± 0.028 0.001† −0.023 ± 0.066 −0.020 ± 0.109 0.002†
*Calculated by χ2 test; †calculated by Mann-Whitney U test. VA = visual acuity.
p = 0.000
p = 0.000
p = 0.000
p = 0.001
0
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Figure 2. (A, B) Comparison between groups A and B of the number of eyes with poor and good visual acuities (VAs) at the first visit and
last visit during the observation period. The end point of follow-up was set in December 1993 for group A in order to have similar follow-
up period for both groups. (C, D) Comparison between males and females of the number of eyes with poor and good VAs at the last visit
during the observation period. Good, middle, and poor VAs were designated ≥ 6/12, 6/60 < VA < 6/12, and ≤ 6/60, respectively. 
The percentage of eyes with good VA increased (p = 0.01, χ2 test), whereas that with poor VA decreased significantly (p = 0.01, χ2 test)
in group B and females.
the Japanese criteria.6,9,17–22 BD is male-predominant
in Turkey, Israel, Lebanon, Egypt, Iran and Greece,
and female-predominant in Japan, Germany, Brazil,
and the United States.7 But BD with ocular involvement
is male-predominant everywhere, with a male-to-female
ratio of 2.1 to 8.9,10,17–23 This ratio was relatively low
(1.6) in our study, and did not significantly change
during the 2-decade period of observation.
There was no significant gender and group differ-
ence in average age of uveitis onset (30.8 years), as
previously reported.9,10,17–23 The most impressive find-
ing (not previously reported) was that prevalence peaked
in the 3rd and 4th decades in males, but was evenly dis-
tributed throughout the period between the 2nd and
5th decades in females. The frequency of binocular
involvement was 84%, which was in the previously
reported range of 64–98%.9,10,17,21–23
Uveitis is one of the most devastating conditions
in BD. The frequency of bilateral involvement ranged
between 78% and 95% in previous reports,9,10,19,22,24
and the result of this study fell within this range.
Panuveitis was the most common type of uveitis in 
2 recent large series, with frequencies of 97.1% and
60.2%, respectively,9,10 and it was similar in this study.
Furthermore, Tugal-Tutkun and his colleagues found
that anterior uveitis was more common in females,
while posterior segment involvement occurred more
frequently in males.10 However, similar results were
not present in this study. In this study, patients with
panuveitis, bilateral involvement and symmetric ocular
manifestations were decreased in group B.
Lower frequency of extraocular manifestations has
been found in BD patients with ocular involvement
than in the general BD population. Oral ulcers are
still the most common lesions (frequency of > 90% 
to 100%).9,10,21–23 In this study, the frequency of 
skin lesions was 50.7% (previously reported range,
51–80%).9,10,21–23 The cause of significantly higher
frequency in males and lower frequency in group B is
unknown. The frequency of genital ulcers was 43.2%
(previously reported range, 41–80%).9,10,21–23 Our
observation of significantly lower frequency in group
B was similar to that reported by Yoshida et al.9 The
frequency of arthritis was as high as 66%, that is, even
higher than the frequency of skin lesions or genital
ulcers. The frequency of neuropsychiatric symptoms
was 12.8%, which was slightly higher than the reported
range (3.8–8.2%).9,10 Gastrointestinal lesions occurred
in 4.0%, similar to the rate found by Yoshida et al,9 but
the reason these lesions all occur in males is unknown.
The number of patients with complete-type BD ap-
peared to be decreased in the second decade, though
this decrease was not statistically significant. The same
tendency was found in Japan.9
High prevalence of HLA-B51 in BD patients has
been found in different ethnic areas.1 In this study, the
incidence of HLA-B51 was 35.7%, much higher than
the 6.03% in 7,137 blood samples from the Min-Nan,25
the largest ethnic group in Taiwan. Only one-third of
patients had HLA-B51 antigen, which indicates that
many factors are still unknown in the pathogenesis 
of BD.
Colchicine is the preferred treatment and has been
widely used in Japan since the 1970s.26 But a double-
blind trial of colchicine in BD revealed that it may
only be useful for less severe cases.27 In this study,
colchicine was the most frequently used drug, but its
usage decreased significantly in the last decade, when
cyclosporin, azathioprine and methotrexate were used
more frequently. Cyclosporin treatment for BD was
first reported in 1985,28 and became popular there-
after.9,21 Currently, our clinic uses a combination of
cyclosporin and low-dose corticosteroid in patients with
posterior segment involvement and multiple recur-
rence. If the combination is not effective enough to
prevent recurrence, azathioprine, methotrexate and
other immunosuppressants are added. When these im-
munosuppressive agents are prescribed systemically,
their possible side effects should be kept in mind, such
as hypertension, hyperglycemia, and hepatorenal toxi-
city for cyclosporin; leukopenia and thrombocytopenia
for azathioprine; leukopenia, hepatorenal toxicity, and
central nervous system toxicity for methotrexate; and
pulmonary fibrosis, jaundice, renal toxicity, bone marrow
suppression, and hemorrhage cystitis for chlorambucil
and cyclophosphamide. Therefore, regular follow-up of
J Chin Med Assoc • October 2008 • Vol 71 • No 10514
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Figure 3. Kaplan-Meier curves showing cumulative survival of
eyes with a potential visual acuity of > 0.1 in male versus female
patients. A censored observation represents irreversible loss of
useful vision (≤ 0.1).
liver function, renal function, complete blood count,
blood pressure, and serum concentration of certain
drugs are mandatory. As the clinical manifestations of
this disease are diverse, multidisciplinary coordination
is essential for optimal care. Ophthalmologists who
take care of these patients should keep close commu-
nication with various specialists to achieve successful
treatment.
To evaluate the visual outcomes in BD, we com-
pared: (1) the number of patients who had lost useful
vision at their last visit and the mean time to this loss;
(2) the γ value; and (3) the risk of vision loss using
Kaplan-Meyer survival analysis. Visual prognosis was
better in females regardless of method of evaluation,
which is consistent with previous reports.10,17,23 How-
ever, the difference between groups was less remark-
able. Although fewer patients lost useful vision and
the γ value was better in group B, Kaplan-Meyer sur-
vival analysis failed to show a significant between-group
difference. The average time to loss of useful vision
was even shorter in group B, although the difference
was not significant. One possible explanation is that
there were more patients with more severe disease in
group B. As ours was the first uveitis clinic in Taiwan,
most patients with uveitis in Taiwan were referred to this
clinic during the first decade of our study. However,
as more ophthalmologists began to treat these patients,
some patients with milder disease were treated at other
medical facilities. One piece of supportive evidence is
the average time between uveitis onset and the first
visit, which was longer in group B than in group A.
We have concluded that the visual prognosis has gen-
erally improved in the last decade, but still a significant
proportion of patients with more severe disease lose
their vision more quickly despite the most aggressive
treatment.
Visual outcome in BD was poor before the 1980s.
Mamo29 reported that vision was lost in an average 
of 3.36 years after the onset of ocular symptoms.
Mishima et al24 found that more than 50% of Japanese
Behcet patients had a visual acuity of ≤ 0.1 in 5 years.
BenEzra and Cohen30 reported that in 74% of eyes,
useful visual acuity was lost in 6–10 years after the
onset of uveitis. In this study, an irreversible visual loss
was found in 19.6% of 409 eyes at the beginning of
the follow-up period, and useful visual acuity was lost
in 19.1% of the other 329 eyes in 6.49 years (4.25
years after the first visit plus 2.24 years from onset to
the first visit). Thus, 38.7% of eyes lost useful vision in
total. The percentage of vision loss was much lower
than that reported 20 years ago.24,29,30 But compared
to the visual outcomes reported in the 2 largest recent
series, 1 from Turkey10 and 1 from Japan,9 the visual
outcome in our series was poorer. Our series had a
risk of loss of useful vision of 22.6% at 5 years, 43.0%
at 10 years, and 58.5% at 15 years, which was worse
than that in Turkish patients.10 In the Turkish series,
survival rate remained stable after around 10 years for
both sexes. However, in our study, stable survival of
eyes occurred only in females while it continuously
declined in males. The rate of visual deterioration was
also worse than that in the Japanese series.9
The number of new patient with BD is decreasing
in Japan.8,9 But our study found no such tendency.
Our data confirm the generally held beliefs that the
prognosis is worse in male patients and that the disease
severity has become milder.9,10 Nevertheless, uveitis in
BD remains a severe sight-threatening disease. Overall,
we think the current information concerning uveitis
with BD in Chinese patients is instructive.
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